Armata Pharmaceuticals Inc

Research Armata Pharmaceuticals Inc (ARMP) on Bullrun: market cap USD 206.53M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 206.53M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 173.80M-USD 26.31Mn/a-4.8USD 8.69MUSD 288.02M-USD 218.60M
FY2024USD 0-USD 18.92M-USD 39.43Mn/a-0.89USD 9.29MUSD 126.52M-USD 48.02M
FY2023n/a-USD 69.05M-USD 55.57Mn/a-1.91USD 13.52MUSD 120.37M-USD 32.07M
FY2022n/a-USD 36.92M-USD 34.69Mn/a-1.08USD 14.85MUSD 38.94MUSD 36.08M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 206.53Mn/an/an/a
20252025-12-31USD 228.79Mn/an/an/a
20242024-12-31USD 66.94Mn/an/an/a
20232023-12-29USD 117.11Mn/an/an/a
20222022-12-30USD 44.82Mn/an/an/a
20212021-12-31USD 148.58Mn/an/an/a

About Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Armata Pharmaceuticals Inc's market cap?

Armata Pharmaceuticals Inc's market capitalization is USD 206.53M.

What does Armata Pharmaceuticals Inc do?

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.